Skip to main content
BeiGene, Ltd. (SHA:688235)
China flag China · Delayed Price · Currency is CNY
247.21
+8.21 (3.44%)
Apr 28, 2025, 2:45 PM CST

BeiGene Revenue

In the year 2024, BeiGene had annual revenue of $3.81B USD with 54.96% growth. BeiGene had revenue of $1.19B in the quarter ending December 31, 2024, with 84.84% growth.

Revenue
$3.81B
Revenue Growth
+54.96%
P/S Ratio
6.92
Revenue / Employee
$346.39K
Employees
11,000
Market Cap
192.33B CNY

Revenue Chart

* This company reports financials in USD.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20243.81B1.35B54.96%
Dec 31, 20232.46B1.04B73.65%
Dec 31, 20221.42B239.64M20.37%
Dec 31, 20211.18B867.41M280.83%
Dec 31, 2020308.87M-119.34M-27.87%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Jiangsu Hengrui Medicine 29.19B
Shenzhen Mindray Bio-Medical Electronics 37.11B
WuXi AppTec 37.92B
Zhangzhou Pientzehuang Pharmaceutical., 10.79B
Aier Eye Hospital Group 20.98B
Sichuan Biokin Pharmaceutical 5.82B
Shanghai United Imaging Healthcare 10.30B
Yunnan Baiyao Group Co.,Ltd 40.03B
Revenue Rankings

BeiGene News

More News